The Wall Street Journal last week reported that some physicians believe more seniors would benefit from GLP-1 receptor agonists, but insurance hurdles, concerns about muscle loss and drug-drug interactions, and other fears seem to be discouraging them. Other reasons GLP-1s are still underused in clinical practice include reimbursement and prior authorizations. Join us this Thursday, Aug. 15 for a program that aims to close this gap by providing the latest clinical insights and effective communication strategies for GLP-1 medications.
NCPA
